India

BMI View: Clinical research organisations (CROs) will increasingly penetrate India's clinical trial sector. Robust economic expansion and relative political stability will support development... 2011-12-02

BMI View: India's pharmaceutical pricing policy is unusually transparent for an emerging market. It also admirably attempts to balance the requirements of the key stakeholders: patients,... 2011-11-11

BMI View: India's healthcare market has strong fundamentals but is constrained by minimal government support, poor oversight, limited foreign investment and a cultural preference for... 2011-11-01

BMI View: India's pharmaceutical market will increasingly attract foreign drugmakers. The government has made a clear statement that it values the contribution of multinationals to... 2011-10-13

BMI View: GlaxoSmithKline (GSK) will acquire and Indian pharmaceutical company or select local medicine brands very shortly, despite the high premiums on these assets. We also believe... 2011-09-28

BMI View: The regulatory environment of India's pharmaceutical market is far below international standards. Rules are poorly designed and implemented improperly. Our key concerns are... 2011-09-19

BMI View: Growth in the number of mobile phone users and wireless subscribers and advances in the innovative application of communication technology has the potential to transform the... 2011-09-05

BMI View: India's pharmaceutical market has entered a brief period of relative deterioration, primarily due to the country's economic slowdown and high inflation, which have negatively... 2011-09-02

BMI Core View: Non-healthcare companies, particularly technology firms, will increasingly enter the medical services sector. Companies see healthcare as a sustainable and expanding... 2011-08-15

BMI Core View: Governments in emerging markets are increasing investment in local biopharmaceutical research and development (R&D), as they become increasingly aware of the importance... 2011-05-05